Clinical Updates & Insights

Share

Our clinical updates provide you with timely information about Memorial Sloan Kettering’s new treatment approaches, key clinical trials, and innovations in detecting and treating many cancers.

Stay Informed

Get the latest information on MSK’s cancer treatments and research sent straight to your inbox with our monthly clinical updates e-newsletter OncoNotes.
Newsletter Sign Up
202 Clinical Updates found
Spine neurosurgeon Ori Barzilai, MD
MSK’s Initial Experience with Next-Level Robotic Surgery for Complex Spine Tumor Resections

Since 2019, MSK has been pioneering the use of robotic surgery for resecting complex, benign paraspinal tumors.
A New Endpoint for Accelerated Approvals in Multiple Myeloma
A New Endpoint for Accelerated Approvals in Multiple Myeloma

MSK played a central role in the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC)’s landmark decision in April 2024 to accept measurable residual disease (MRD) as an intermediate clinical endpoint for accelerated approval of new drugs and new indications in multiple myeloma clinical trials.
The Main Cause of Non-Relapse Mortality after CAR T Cell Therapy is Not What You Think
Post-Transplantation Prophylaxis Resulted in Similar Outcomes for Mismatched and Matched Donor Stem Cell Transplants

According to a large retrospective study co-led by Memorial Sloan Kettering Cancer Center and published in the Journal of Clinical Oncology, PTCy is an acceptable alternative to CNI-based prophylaxis in MUD HCT recipients and superior for MMUD HCT. These results will help improve minority donor participation in the NMDP registry.
The Main Cause of Non-Relapse Mortality after CAR T Cell Therapy is Not What You Think
The Main Cause of Non-Relapse Mortality after CAR T Cell Therapy is Not What You Think

A recent study led by investigators at MSK and published in Nature Medicine, included a comprehensive analysis of non relapse mortality after CAR T cell therapy in patients with lymphoma and multiple myeloma across multiple clinical trials and real-world studies. In this Q&A we discuss the study's key findings and a new tool for assessing infection risk prior to CAR T cell therapy.
E-Nose Technology Detects Early-Stage Lung Cancer with High Reliability in MSK-Exclusive Trial
E-Nose Technology Detects Early-Stage Lung Cancer with High Reliability in MSK-Exclusive Trial

Electronic nose (e-nose) technology identified early-stage lung cancer with high reliability in a prospective observational clinical trial conducted at Memorial Sloan Kettering Cancer Center (MSK).
MSK ASCO 2024 Research Roundup: Practice-Changing Advances in Head and Neck Cancer, Tenosynovial Giant Cell Tumor, Kidney Cancer, Lung Cancer, and More Add to Default shortcuts
MSK ASCO 2024 Research Roundup: Practice-Changing Advances in Head and Neck Cancer, Tenosynovial Giant Cell Tumor, Kidney Cancer, Lung Cancer, and More

MSK physician-scientists presented breakthrough advances in new treatment approaches for several cancer types at the 2024 ASCO Annual Meeting.
MSK Clinical Trials for Patients with BCG-Naïve, BCG-Exposed, and BCG-Unresponsive Bladder Cancer
A New Era in Bladder Cancer Research at MSK

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) are conducting a range of clinical trials of promising new treatments for patients with non-muscle invasive bladder cancer (NMIBC).
A Q&A with MSK’s Dr. Jonathan Coleman
Kidney-Sparing Treatment Options for Upper Tract Urothelial Carcinoma With and Without Lynch Syndrome

MSK’s comprehensive program for patients with upper tract urothelial carcinoma (UTUC) offers kidney-sparing treatment options whenever possible.
MSK AACR 2024 Research Roundup: Highlights of Exciting Advances in Foundational and Translational Research
MSK AACR 2024 Research Roundup: Highlights of Exciting Advances in Foundational and Translational Research

Memorial Sloan Kettering Cancer Center (MSK) experts presented findings from their latest foundational and translational cancer research at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5 to 10 in San Diego.
Adoptive Cell Therapy Improves Outcomes for Select Patients With Advanced Synovial Sarcoma
Adoptive Cell Therapy Improves Outcomes for Select Patients With Advanced Synovial Sarcoma

The adoptive cell therapy afamitresgene autoleucel (afami-cel) demonstrated a favorable response and duration of response in select patients with metastatic synovial sarcoma, according to results from an international phase 2 clinical trial published recently in The Lancet.